However, dual-targeted CAR-T directed at GPC-3 and asialo-glycoprotein receptor (ASRG1) exerted superior anticancer activity and persistence than single-targeted CAR-T cells in two GPC3+ASGR1+HCC xenograft models [146]. The gene discussed is ASGR1; the disease is hepatocellular carcinoma.